EA200500547A1 - Конструкции нуклеиновых кислот для экспрессии генов - Google Patents

Конструкции нуклеиновых кислот для экспрессии генов

Info

Publication number
EA200500547A1
EA200500547A1 EA200500547A EA200500547A EA200500547A1 EA 200500547 A1 EA200500547 A1 EA 200500547A1 EA 200500547 A EA200500547 A EA 200500547A EA 200500547 A EA200500547 A EA 200500547A EA 200500547 A1 EA200500547 A1 EA 200500547A1
Authority
EA
Eurasian Patent Office
Prior art keywords
endogenous
nucleic acid
elements
regulation
gene expression
Prior art date
Application number
EA200500547A
Other languages
English (en)
Other versions
EA008247B1 (ru
Inventor
Ральф Патрик Браун
Original Assignee
Паудерджект Рисерч Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Паудерджект Рисерч Лимитед filed Critical Паудерджект Рисерч Лимитед
Publication of EA200500547A1 publication Critical patent/EA200500547A1/ru
Publication of EA008247B1 publication Critical patent/EA008247B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C12N15/8695—Herpes simplex virus-based vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к конструкциям нуклеиновой кислоты, содержащим вирусную геномную нуклеиновую кислоту, которая включает по меньшей мере два эндогенных элемента регуляции экспрессии гена, каждый из которых содержит эндогенный промотор, где указанные эндогенные промоторы указанных элементов являются активными в одной и той же фазе жизненного цикла вируса, от которого происходит указанная вирусная геномная нуклеиновая кислота. Эндогенные элементы регуляции экспрессии гена используют для экспрессии конкретно выбранных гетерологичных кодирующих последовательностей, а в частности для экспрессии гетерологичных антигенов. Указанные конструкции могут быть использованы в вакцине для продуцирования иммунного ответа против гетерологичных антигенов, а в частности они могут быть использованы в ДНК-вакцине. Настоящее изобретение также относится к способам получения таких конструкций и к способам их введения.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500547A 2002-09-27 2003-09-29 Конструкции нуклеиновых кислот для экспрессии генов EA008247B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41408902P 2002-09-27 2002-09-27
PCT/GB2003/004218 WO2004029258A1 (en) 2002-09-27 2003-09-29 Nucleic acid constructs for gene expression

Publications (2)

Publication Number Publication Date
EA200500547A1 true EA200500547A1 (ru) 2005-12-29
EA008247B1 EA008247B1 (ru) 2007-04-27

Family

ID=32043343

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500547A EA008247B1 (ru) 2002-09-27 2003-09-29 Конструкции нуклеиновых кислот для экспрессии генов

Country Status (16)

Country Link
US (1) US20050272030A1 (ru)
EP (1) EP1546347A1 (ru)
JP (1) JP2006500062A (ru)
KR (1) KR20050062565A (ru)
CN (1) CN1701120A (ru)
AU (1) AU2003269220A1 (ru)
BR (1) BR0314769A (ru)
CA (1) CA2500270A1 (ru)
EA (1) EA008247B1 (ru)
GB (1) GB2409681B (ru)
HK (1) HK1073669A1 (ru)
MX (1) MXPA05003225A (ru)
NZ (1) NZ539647A (ru)
PL (1) PL376053A1 (ru)
WO (1) WO2004029258A1 (ru)
ZA (1) ZA200503377B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
JP2010508828A (ja) * 2006-11-10 2010-03-25 マーシャル，バリー，ジェー． 胃粘膜内へのペプチド送達方法及び装置
SI2516629T1 (sl) 2009-12-21 2016-10-28 The Brigham And Women's Hospital, Inc. Cepiva proti virusu herpes simplex
WO2011150235A1 (en) * 2010-05-27 2011-12-01 Allertein Therapeutics, Llc Methods and reagents for treating autoimmune disorders and/or graft rejection
JP5957443B2 (ja) * 2011-03-28 2016-07-27 長瀬産業株式会社 フェリチンの製造方法
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
WO2019231929A1 (en) * 2018-05-29 2019-12-05 Buck Institute For Research On Aging Gene-drive in dna viruses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
EP0251575B2 (en) * 1986-06-17 2002-11-13 Chiron Corporation Hepatitis delta diagnostics and vaccines, their preparation and use
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5162222A (en) * 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
DE69529495T2 (de) * 1994-01-21 2003-06-12 Powderject Vaccines Inc Gasbetätigtes element zum austragen von genmaterial
FR2715664B1 (fr) * 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US5876923A (en) * 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
GB9700411D0 (en) * 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses

Also Published As

Publication number Publication date
EA008247B1 (ru) 2007-04-27
JP2006500062A (ja) 2006-01-05
CA2500270A1 (en) 2004-04-08
US20050272030A1 (en) 2005-12-08
PL376053A1 (en) 2005-12-12
ZA200503377B (en) 2007-11-28
KR20050062565A (ko) 2005-06-23
AU2003269220A1 (en) 2004-04-19
HK1073669A1 (en) 2005-10-14
GB2409681A (en) 2005-07-06
WO2004029258A1 (en) 2004-04-08
GB2409681B (en) 2007-03-28
MXPA05003225A (es) 2005-07-05
GB0508088D0 (en) 2005-06-01
EP1546347A1 (en) 2005-06-29
CN1701120A (zh) 2005-11-23
BR0314769A (pt) 2005-07-26
NZ539647A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
RU2733834C1 (ru) Искусственный ген EctoS_SC2, кодирующий эктодомен гликопротеина S коронавируса SARS-CoV-2 с C-концевым тримеризующим доменом, рекомбинантная плазмида pStem-rVSV-EctoS_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-EctoS_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
EA202092990A3 (ru) Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
JP2005502355A5 (ru)
EA200701643A1 (ru) Конструкции нуклеиновых кислот
EP1157123A1 (en) Stable recombinant influenza viruses free of helper viruses
DK1211318T3 (da) Paramyxovira omfattende en modificeret transkriptionsstartsekvens
JP2015522581A5 (ru)
EP2434020A3 (en) Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter
ES2170622B1 (es) Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
SG55158A1 (en) Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
ATE366314T1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
ATE483815T1 (de) Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren
BRPI0612268A2 (pt) Ácido nucleico isolado, vetor de expressço, mÉtodos para produzir um rna genâmico da influenza, para produzir um vÍrus da influenza recombinante, para gerar um vÍrus de rna segmentado de filamento negativo recombinante nas cÉlulas caninas cultivadas e para gerar partÍculas virais da influenza infecciosa em cÉlulas caninas cultivadas, cÉlula, e, vÍrus
RU2008106445A (ru) Вирусоподобные корпускулы (частицы) в качестве противопарамиксовирусной вакцины
RU2014120408A (ru) Рекомбинантный непатогенный mdv-вектор, обеспечивающий полиспецифический иммунитет
JP2013507935A5 (ru)
JP2015119730A5 (ru)
JP2014514921A5 (ru)
HUP9800329A2 (hu) Nukleinsavkonstrukciók strukturális gének sejtciklus-függő módon szabályozott expresszálására
EA200500547A1 (ru) Конструкции нуклеиновых кислот для экспрессии генов
HUP0001817A2 (hu) Chlorella víruspromóterek
Ye et al. Gene synthesis and expression in E. coli for pump, a human matrix metalloproteinase
DK1585822T3 (da) Promotorvarianter til ekspression af gener i en fungal celle
CN112680443A (zh) 一种启动子pCalm1及其应用
Acosta-Rivero et al. Improvement of human interferon HUIFNα2 and HCV core protein expression levels in Escherichia coli but not of HUIFNα8 by using the tRNAAGA/AGG

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU